NCT07001059 oPtic Nerve Sheath Evaluation in gianT Cell aRtheritis by UltraSound
| NCT ID | NCT07001059 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hôpital NOVO |
| Condition | Giant Cell Arteritis (GCA) |
| Study Type | INTERVENTIONAL |
| Enrollment | 190 participants |
| Start Date | 2025-09-04 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 190 participants in total. It began in 2025-09-04 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate whether the measure of the optic nerve sheath is a reliable diagnostic marker for giant cell arteritis
Eligibility Criteria
Inclusion Criteria: * Patient with suspected GCA * Patient over 50 years Exclusion Criteria: * Patient with history of GCA * Patient with a history of polymyalgia rheumatic (PMR) without initial PET scan * Patient with a history of retinal disease, demyelinating disease, or intracranial hypertension * Use of corticosteroids \> 0.5mg/kg in the last 2 weeks
Contact & Investigator
Omar AL TABAA, Dr
PRINCIPAL INVESTIGATOR
Hôpital NOVO
Frequently Asked Questions
Who can join the NCT07001059 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Giant Cell Arteritis (GCA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07001059 currently recruiting?
Yes, NCT07001059 is actively recruiting participants. Contact the research team at maryline.delattre@ght-novo.fr for enrollment information.
Where is the NCT07001059 trial being conducted?
This trial is being conducted at Aix-en-Provence, France, Brest, France, Caen, France, Dijon, France and 5 additional locations.
Who is sponsoring the NCT07001059 clinical trial?
NCT07001059 is sponsored by Hôpital NOVO. The principal investigator is Omar AL TABAA, Dr at Hôpital NOVO. The trial plans to enroll 190 participants.